Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus ...

UCB and Biogen (BIIB) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its investigational ...

“Treatments for discoid lupus erythematosus often focus on addressing skin symptoms over known systemic complications, such ...

A new study found a strong connection between azathioprine exposure and development of ICP in women with systemic lupus erythematosus (SLE).

Women with systemic lupus erythematosus had fewer second deliveries and higher recurrence of adverse pregnancy outcomes in ...

Decision aid clarifies benefits and risks; trial shows it improved adherence ...

Adverse drug effects commonly occur in patients with rheumatologic diseases, most of whom take multiple medications to ...

Black women are three times more likely to be diagnosed with systemic lupus erythematosus (SLE), the most common form of ...